pharmaceuticals

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Are Shareholders Getting Enough in the Achillion Acquisition?

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). While shares are up sharply ...
Read Full Story »

Why This Neuromuscular Disorder Study Could Be the Next Big Thing

Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial. Specifically, the results are from Reata’s MOXIe Phase ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday. The consensus estimates are calling for $2.00 in earnings per ...
Read Full Story »

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Allergan PLC (NYSE: AGN) finally has announced that its shareholders have voted to approve the company’s acquisition by AbbVie Inc. (NYSE: ABBV). The acquisition is expected to close in early ...
Read Full Story »

Are Shareholders Getting Enough From the Ra Pharma Acquisition?

Ra Pharmaceuticals Inc. (NASDAQ: RARX) shares more than doubled on Thursday after the announcement that UCB would acquire the firm. The boards of directors of both companies have unanimously approved ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

The announcement that a jury has awarded $8 billion in damages to a man accusing Johnson & Johnson (NYSE: JNJ) of failing to warn about the side effects of ...
Read Full Story »

Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study

Eli Lilly and Co. (NYSE: LLY) announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the Fifth Annual Maui Derm NP+PA Fall meeting. ...
Read Full Story »

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Johnson & Johnson (NYSE: JNJ) surprised investors on Wednesday morning by announcing a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial. While this in and ...
Read Full Story »

FDA Accepts for Review the Newest Treatment for C Diff

Merck & Co. Inc. (NYSE: MRK) has just announced that the U.S. Food and Drug Administration (FDA) accepted a couple New Drug Applications (NDAs) for review. Specifically, the FDA accepted ...
Read Full Story »

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April. Even the biggest and ...
Read Full Story »

Major Duchenne Muscular Dystrophy Trial Is Ready to Launch

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment is for the Phase 3 PolarisDMD trial ...
Read Full Story »

Are Dova Pharma Investors Getting the Most Out of This Acquisition?

Dova Pharmaceuticals Inc. (NASDAQ: DOVA) shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. Through this acquisition, Sobi is looking ...
Read Full Story »

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

With the final quarter of 2019 beginning next Tuesday, many investors are taking a long hard look at their portfolios and trying to make some adjustments. While the end of ...
Read Full Story »